Hanmi to patent human growth hormone in liquid composite.

Published: 2006-02-13 07:00:00

Updated: 2006-02-13 07:00:00

Hanmi has registered a patent for a stabilized liquid form of human growth hormone composite in Korea, which was developed by 2,850 million won of investment. The discovery showed not to use conventional preservatives and surfactants in liquid preparations but only to use PEG to improve the safet...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK